Approval · Notice of Compliance 1059 · 2000
DOVONEX: Notice of Compliance 1059
Issued April 4, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1059
- Date
- April 4, 2000
- Company
- Leo Pharma IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revised dosage regimen revised indication: treatment of psoriasis new indication: combination therapy - use with topical corticosteroids, cyclosprorin a, acitretin and/or phototherapy (puva or uvb)
- Therapeutic class
- Topical non-steroidal, antipsoriatic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DOVONEX | Not yet assigned | — |
Medicinal ingredients
- CALCIPOTRIOL 50 MCG per G